Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

John Imig

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentCOP | College of Pharmacy
Address4301 W Markham
Little Rock AR 72205
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    1T32TR004918-01     (IMIG, JOHN)Jul 1, 2024 - Jun 30, 2029
    NIH/National Center for Advancing Translational Sciences
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Principal Investigator
    1T32TR004918-02     (IMIG, JOHN)Jul 1, 2024 - Jun 30, 2029
    NIH/National Center for Advancing Translational Sciences
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Principal Investigator
    1T32TR004918-03     (IMIG, JOHN)Jul 1, 2024 - Jun 30, 2029
    NIH/National Center for Advancing Translational Sciences
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Principal Investigator
    1T32TR004918-04     (IMIG, JOHN)Jul 1, 2024 - Jun 30, 2029
    NIH/National Center for Advancing Translational Sciences
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Principal Investigator
    1T32TR004918-05     (IMIG, JOHN)Jul 1, 2024 - Jun 30, 2029
    NIH/National Center for Advancing Translational Sciences
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Principal Investigator
    T32TR004918     (SEXTON, KEVIN WAYNE)Jul 1, 2024 - Jun 30, 2029
    NIH
    CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
    Role: Co-Principal Investigator
    R01DK133197     (IMIG, JOHN)Apr 1, 2024 - Mar 31, 2026
    NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases - Pass Through: Medical College of Wisconsin
    Theophylline Prophylaxis during Hypothermia to Limit Neonatal Nephron Damage
    Role: Principal Investigator
    5R01DK126452-04     (IMIG, JOHN)Feb 2, 2023 - May 31, 2026
    NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases
    Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
    Role: Principal Investigator
    5R01DK126452-05     (IMIG, JOHN)Feb 2, 2023 - May 31, 2026
    NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases
    Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
    Role: Principal Investigator
    5R01DK126452-06     (IMIG, JOHN)Feb 2, 2023 - May 31, 2026
    NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases
    Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
    Role: Principal Investigator
    7R01DK126452-03     (IMIG, JOHN)Feb 2, 2023 - May 31, 2026
    NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases
    Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
    Role: Principal Investigator
    5R01HL147976     (IMIG, JOHN)Oct 1, 2022 - Jun 30, 2023
    NIH/National Institutes of Health - Pass Through: Medical College of Wisconsin
    Role of p66Shc in Regulation of Microvascular Reactivity of Renal Blood Vessels
    Role: Principal Investigator
    5R01HL147976-04     (IMIG, JOHN)Oct 1, 2022 - Jun 30, 2023
    NIH/Nat. Heart, Lung & Blood Institute - Pass Through: Medical College of Wisconsin
    Role of p66Shc in Regulation of Microvascular Reactivity of Renal Blood Vessels
    Role: Principal Investigator
    R01DK126452     (IMIG, JOHN D)Jun 1, 2021 - May 31, 2026
    NIH
    Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
    Role: Principal Investigator
    R01DK103616     (IMIG, JOHN D)Aug 20, 2015 - Jun 30, 2021
    NIH
    Eicosanoid-based Therapy for Diabetes
    Role: Principal Investigator
    R41NS053002     (IMIG, JOHN D)Aug 30, 2005 - Aug 31, 2007
    NIH
    Novel epoxide hydrolase inhibitor for stroke prevention
    Role: Principal Investigator
    R01HL059699     (IMIG, JOHN D)Jan 1, 1998 - May 31, 2013
    NIH
    Epoxyeicosanoids and Renal Vascular Function in Obesity &Hypertension
    Role: Principal Investigator
    R29HL059699     (IMIG, JOHN D)Jan 1, 1998 - Dec 31, 2001
    NIH
    OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY
    Role: Principal Investigator
    F32DK008676     (IMIG, JOHN D)Sep 1, 1992
    NIH
    CYTOCHROME P450 AND NO IN CONTROL OF RENAL VASCULAR TONE
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Miller B, Imig JD, Li M, Schupbach P, Woo S, Benbrook DM, Sorokin A. Prevention of hypertension-induced renal vascular dysfunction through a p66Shc-targeted mechanism. Am J Physiol Renal Physiol. 2025 May 01; 328(5):F693-F701. PMID: 40172516.
      View in: PubMed
    2. de Bourg M, Mishra A, Mohammad RS, Morisseau C, Hammock BD, Imig JD, Vik A. Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death. Molecules. 2025 Mar 24; 30(7). PMID: 40286028.
      View in: PubMed
    3. Maranto C, Udhane V, Jia J, Verma R, M?ller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. Cancers (Basel). 2025 Mar 10; 17(6). PMID: 40149386.
      View in: PubMed
    4. Goorani S, Zangene S, Imig JD. Hypertension: A Continuing Public Healthcare Issue. Int J Mol Sci. 2024 Dec 26; 26(1). PMID: 39795981.
      View in: PubMed
    5. Gawrys O, J?chov? ?, Miklovic M, Huskov? Z, Kikerlov? S, Sadowski J, Koll?rov? P, Lencov?-Popelova O, Ho?kov? L, Imig JD, Mazurova Y, Kol?r F, Melenovsk? V, ?terba M, Cervenka L. Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats. Hypertens Res. 2024 Nov; 47(11):3126-3146. PMID: 39245782.
      View in: PubMed
    6. Goorani S, Khan AH, Mishra A, El-Meanawy A, Imig JD. Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences. Kidney Blood Press Res. 2024; 49(1):69-80. PMID: 38185105.
      View in: PubMed
    7. Khan MAH, Nolan B, Stavniichuk A, Merk D, Imig JD. Dual soluble epoxide hydrolase inhibitor - farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis. Front Immunol. 2023; 14:1269261. PMID: 38235144.
      View in: PubMed
    8. Imig JD, Wu J, Gohar EY. Editorial: Nuclear receptors in hemodynamics and blood pressure control. Front Physiol. 2023; 14:1290411. PMID: 37829111.
      View in: PubMed
    9. Imig JD. Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension. Front Physiol. 2023; 14:1186477. PMID: 37427406.
      View in: PubMed
    10. Imig JD. Bioactive lipids in hypertension. Adv Pharmacol. 2023; 97:1-35. PMID: 37236756.
      View in: PubMed
    11. Imig JD. Editorial: The future of physiology: 2020 and beyond, Volume III. Front Physiol. 2023; 14:1159406. PMID: 36935750.
      View in: PubMed
    12. Imig JD, Khan MAH, Stavniichuk A, Jankiewicz WK, Goorani S, Yeboah MM, El-Meanawy A. Salt-sensitive hypertension after reversal of unilateral ureteral obstruction. Biochem Pharmacol. 2023 04; 210:115438. PMID: 36716827.
      View in: PubMed
    13. Imig JD. Osteopontin Regulates Phosphate Solubility to Prevent Mineral Aggregates in CKD. Kidney360. 2022 09 29; 3(9):1477-1479. PMID: 36245661.
      View in: PubMed
    14. Imig JD. Frontiers in metabolic physiology grand challenges. Front Physiol. 2022; 13:879617. PMID: 36035475.
      View in: PubMed
    15. Imig JD. SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clin Sci (Lond). 2022 03 31; 136(6):431-434. PMID: 35348182.
      View in: PubMed
    16. Imig JD. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Adv Pharmacol. 2022; 94:27-55. PMID: 35659375.
      View in: PubMed
    17. Imig JD, Zhao X, Elmarakby AA, Pavlov T. Editorial: Interactions Between Podocytes, Mesangial Cells, and Glomerular Endothelial Cells in Glomerular Diseases. Front Physiol. 2022; 13:849693. PMID: 35399279.
      View in: PubMed
    18. Chiang KC, Rizk JG, Nelson DJ, Krishnamurti L, Subbian S, Imig JD, Khan I, Reddy ST, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opin Ther Targets. 2022 01; 26(1):13-28. PMID: 35068281.
      View in: PubMed
    19. Baranowska I, Gawrys O, Walkowska A, Olszynski KH, Cervenka L, Falck JR, Adebesin AM, Imig JD, Kompanowska-Jezierska E. Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats. Front Pharmacol. 2021; 12:798642. PMID: 35111064.
      View in: PubMed
    20. Chiang KC, Imig JD, Kalantar-Zadeh K, Gupta A. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Curr Opin Nephrol Hypertens. 2022 01 01; 31(1):36-46. PMID: 34846312.
      View in: PubMed
    21. Jankiewicz WK, Barnett SD, Stavniichuk A, Hwang SH, Hammock BD, Belayet JB, Khan AH, Imig JD. Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. Front Pharmacol. 2021; 12:744776. PMID: 34955823.
      View in: PubMed
    22. Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochem Pharmacol. 2022 01; 195:114866. PMID: 34863976.
      View in: PubMed
    23. George J, Zhang Y, Sloan J, Sims JM, Imig JD, Zhao X. Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. Front Immunol. 2021; 12:747794. PMID: 34675931.
      View in: PubMed
    24. Widiapradja A, Kasparian AO, McCaffrey SL, Kolb LL, Imig JD, Lacey JL, Melendez GC, Levick SP. Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. Cells. 2021 10 05; 10(10). PMID: 34685639.
      View in: PubMed
    25. Kala P, Miklovic M, J?chov? ?, ?karoupkov? P, Vanourkov? Z, Maxov? H, Gawrys O, Kompanowska-Jezierska E, Sadowski J, Imig JD, Falck JR, Veselka J, Cervenka L, Aiglov? R, V?cha M, Gloger V, T?borsk? M. Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. Biomedicines. 2021 Aug 20; 9(8). PMID: 34440257.
      View in: PubMed
    26. Khan MAH, Hwang SH, Barnett SD, Stavniichuk A, Jankiewicz WK, Hammock BD, Imig JD. Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. Br J Pharmacol. 2021 11; 178(22):4468-4484. PMID: 34255857.
      View in: PubMed
    27. Imig JD, Merk D, Proschak E. Multi-Target Drugs for Kidney Diseases. Kidney360. 2021 10 28; 2(10):1645-1653. PMID: 35372984.
      View in: PubMed
    28. Imig JD. Diabetes risk associated with plasma epoxylipid levels. EBioMedicine. 2021 04; 66:103331. PMID: 33857907.
      View in: PubMed
    29. Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol. 2020; 11:554961. PMID: 33776749.
      View in: PubMed
    30. Imig JD, Hye Khan MA, Burkhan A, Chen G, Adebesin AM, Falck JR. Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. Int J Mol Sci. 2021 Mar 10; 22(6). PMID: 33801911.
      View in: PubMed
    31. Walkowska A, Cervenka L, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E. Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. Front Physiol. 2021; 12:622882. PMID: 33584348.
      View in: PubMed
    32. Klemens CA, Chulkov EG, Wu J, Hye Khan MA, Levchenko V, Flister MJ, Imig JD, Kriegel AJ, Palygin O, Staruschenko A. Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. Hypertension. 2021 02; 77(2):582-593. PMID: 33390052.
      View in: PubMed
    33. Imig JD, Hye Khan MA, Zhao X. Editorial: Renal Function in Acute and Chronic Kidney Diseases. Front Physiol. 2020; 11:625353. PMID: 33343402.
      View in: PubMed
    34. Maranto C, Udhane V, Jia J, Verma R, M?ller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers (Basel). 2020 Nov 18; 12(11). PMID: 33217941.
      View in: PubMed
    35. Imig JD. Eicosanoid blood vessel regulation in physiological and pathological states. Clin Sci (Lond). 2020 10 30; 134(20):2707-2727. PMID: 33095237.
      View in: PubMed
    36. Imig JD, Morisseau C. Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors. Front Pharmacol. 2020; 11:598858. PMID: 33071800.
      View in: PubMed
    37. Gawrys O, Huskov? Z, Baranowska I, Walkowska A, Sadowski J, Kikerlov? S, Vanourkov? Z, Honetschl?gerov? Z, ?karoupkov? P, Cervenka L, Falck JR, Imig JD, Kompanowska-Jezierska E. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. J Hypertens. 2020 09; 38(9):1802-1810. PMID: 32384390.
      View in: PubMed
    38. Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Bl?cher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 10; 150:106472. PMID: 32569747.
      View in: PubMed
    39. Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15. PMID: 32475311.
      View in: PubMed
    40. Stavniichuk A, Savchuk O, Khan AH, Jankiewicz WK, Imig JD. A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE. Visnyk Kyivskoho Natsionalnoho Universytetu Imeni Tarasa Shevchenka Biolohiia. 2020; 81(2):25-31. PMID: 33251532.
      View in: PubMed
    41. Stavniichuk A, Savchuk O, Khan AH, Jankiewicz WK, Imig JD, Merk D. THE EFFECT OF COMPOUND DM509 ON KIDNEY FIBROSIS IN THE CONDITIONS OF THE EXPERIMENTAL MODEL. Visnyk Kyivskoho Natsionalnoho Universytetu Imeni Tarasa Shevchenka Biolohiia. 2020; 80(1):10-15. PMID: 33437972.
      View in: PubMed
    42. Cert?kov? Ch?bov? V, Kujal P, Vanourkov? Z, ?karoupkov? P, Sadowski J, Kompanowska-Jezierska E, Tesar V, Hammock B, Imig J, Maxov? H, Cervenka L, Vaneckov? I. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney Blood Press Res. 2019; 44(6):1493-1505. PMID: 31770762.
      View in: PubMed
    43. Vackov? ?, Kikerlov? S, Melenovsky V, Kol?r F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney Blood Press Res. 2019; 44(4):792-809. PMID: 31430751.
      View in: PubMed
    44. Widiapradja A, Manteufel EJ, Dehlin HM, Pena J, Goldspink PH, Sharma A, Kolb LL, Imig JD, Janicki JS, Lu B, Levick SP. Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. Sci Rep. 2019 07 29; 9(1):11004. PMID: 31358823.
      View in: PubMed
    45. Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol. 2019 08; 166:212-221. PMID: 31129048.
      View in: PubMed
    46. Hye Khan MA, Stavniichuk A, Sattar MA, Falck JR, Imig JD. Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. Front Pharmacol. 2019; 10:512. PMID: 31133860.
      View in: PubMed
    47. Neck?r J, Hye Khan MA, Gross GJ, Cyprov? M, Hrdlicka J, Kvasilov? A, Falck JR, Campbell WB, Sedl?kov? L, ?kutov? ?, Olejn?ckov? V, Gregorovicov? M, Sedmera D, Kol?r F, Imig JD. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clin Sci (Lond). 2019 04 30; 133(8):939-951. PMID: 30979784.
      View in: PubMed
    48. Hrdlicka J, Neck?r J, Papou?ek F, Huskov? Z, Kikerlov? S, Vanourkov? Z, Vernerov? Z, Akat F, Va?inov? J, Hammock BD, Hwang SH, Imig JD, Falck JR, Cervenka L, Kol?r F. Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. Front Pharmacol. 2019; 10:159. PMID: 30881303.
      View in: PubMed
    49. Vackov? ?, Kopkan L, Kikerlov? S, Huskov? Z, Sadowski J, Kompanowska-Jezierska E, Hammock BD, Imig JD, T?borsk? M, Melenovsk? V, Cervenka L. Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. Front Pharmacol. 2019; 10:18. PMID: 30728778.
      View in: PubMed
    50. Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203. PMID: 30307705.
      View in: PubMed
    51. Sedl?kov? L, Kikerlov? S, Huskov? Z, Cervenkov? L, Ch?bov? VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kr?tk? V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5). PMID: 30054426.
      View in: PubMed
    52. Miller BS, Blumenthal SR, Shalygin A, Wright KD, Staruschenko A, Imig JD, Sorokin A. Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. Diabetes. 2018 11; 67(11):2206-2212. PMID: 30131395.
      View in: PubMed
    53. Neck?r J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprov? M, Ben?k D, Hlav?ckov? M, Sot?kov?-Ka?parov? D, Falck JR, Sedmera D, Kol?r F, Imig JD. Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1a via downregulation of prolyl hydroxylase 3. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1148-H1158. PMID: 30074840.
      View in: PubMed
    54. Yeboah MM, Hye Khan MA, Chesnik MA, Skibba M, Kolb LL, Imig JD. Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. Nephrol Dial Transplant. 2018 08 01; 33(8):1333-1343. PMID: 29361048.
      View in: PubMed
    55. Hye Khan MA, Kolb L, Skibba M, Hartmann M, Bl?cher R, Proschak E, Imig JD. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 10; 61(10):2235-2246. PMID: 30032428.
      View in: PubMed
    56. Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018 12; 192:1-19. PMID: 29964123.
      View in: PubMed
    57. Cervenka L, Huskov? Z, Kopkan L, Kikerlov? S, Sedl?kov? L, Vanourkov? Z, Al?nov? P, Kol?r F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neck?r J. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. J Hypertens. 2018 06; 36(6):1326-1341. PMID: 29570510.
      View in: PubMed
    58. Cert?kov? Ch?bov? V, Kujal P, ?karoupkov? P, Varnourkov? Z, Vackov? ?, Huskov? Z, Kikerlov? S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesar V, Cervenka L. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):329-349. PMID: 29529602.
      View in: PubMed
    59. Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017 Oct; 70(4):211-224. PMID: 28937442.
      View in: PubMed
    60. Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765. PMID: 28757338.
      View in: PubMed
    61. Skibba M, Hye Khan MA, Kolb LL, Yeboah MM, Falck JR, Amaradhi R, Imig JD. Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. Front Pharmacol. 2017; 8:406. PMID: 28713267.
      View in: PubMed
    62. Gangadhariah MH, Dieckmann BW, Lantier L, Kang L, Wasserman DH, Chiusa M, Caskey CF, Dickerson J, Luo P, Gamboa JL, Capdevila JH, Imig JD, Yu C, Pozzi A, Luther JM. Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia. 2017 06; 60(6):1066-1075. PMID: 28352940.
      View in: PubMed
    63. J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25. PMID: 27428043.
      View in: PubMed
    64. Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat. 2016 09; 125:40-7. PMID: 27432695.
      View in: PubMed
    65. Yeboah MM, Hye Khan MA, Chesnik MA, Sharma A, Paudyal MP, Falck JR, Imig JD. The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. Am J Physiol Renal Physiol. 2016 09 01; 311(3):F576-85. PMID: 27358055.
      View in: PubMed
    66. Miller B, Palygin O, Rufanova VA, Chong A, Lazar J, Jacob HJ, Mattson D, Roman RJ, Williams JM, Cowley AW, Geurts AM, Staruschenko A, Imig JD, Sorokin A. p66Shc regulates renal vascular tone in hypertension-induced nephropathy. J Clin Invest. 2016 07 01; 126(7):2533-46. PMID: 27270176.
      View in: PubMed
    67. Sharma A, Hye Khan MA, Levick SP, Lee KS, Hammock BD, Imig JD. Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. Int J Mol Sci. 2016 May 18; 17(5). PMID: 27213332.
      View in: PubMed
    68. Imig JD, Hye Khan MA, Sharma A, Fish BL, Mandel NS, Cohen EP. Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. Am J Physiol Heart Circ Physiol. 2016 06 01; 310(11):H1695-701. PMID: 27106038.
      View in: PubMed
    69. Imig JD. Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response? Am J Physiol Renal Physiol. 2016 05 15; 310(10):F1013-5. PMID: 26962100.
      View in: PubMed
    70. Sporkov? A, Reddy RN, Falck JR, Imig JD, Kopkan L, Sadowski J, Cervenka L. Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. Am J Med Sci. 2016 05; 351(5):513-9. PMID: 27140711.
      View in: PubMed
    71. Hye Khan MA, Fish B, Wahl G, Sharma A, Falck JR, Paudyal MP, Moulder JE, Imig JD, Cohen EP. Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin Sci (Lond). 2016 Apr; 130(8):587-99. PMID: 26772189.
      View in: PubMed
    72. Hye Khan MA, Sharma A, Rarick KR, Roman RJ, Harder DR, Imig JD. Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. PLoS One. 2015; 10(12):e0145335. PMID: 26683993.
      View in: PubMed
    73. Imig JD, Khan MA. Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. Compr Physiol. 2015 Dec 15; 6(1):423-41. PMID: 26756638.
      View in: PubMed
    74. Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA. Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signal. 2015 Dec; 11(4):519-31. PMID: 26385692.
      View in: PubMed
    75. Al?nov? P, Huskov? Z, Kopkan L, Sporkov? A, J?chov? ?, Neck?r J, Imig JD, Klevstig M, Kol?r F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovsk? V, Cervenkov? L, Kujal P, Vernerov? Z, Cervenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015 Oct; 73:45-56. PMID: 26304700.
      View in: PubMed
    76. Sullivan JC, Imig JD. Reply to "Letter to the editor: 'Concern regarding quantification of urinary nephrin by commercially available ELISA'". Am J Physiol Renal Physiol. 2015 Aug 01; 309(3):F271. PMID: 26357487.
      View in: PubMed
    77. Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015 Mar; 65(3):476-82. PMID: 25583156.
      View in: PubMed
    78. Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13. PMID: 25224811.
      View in: PubMed
    79. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F131-9. PMID: 25377915.
      View in: PubMed
    80. Hye Khan MA, Pavlov TS, Christain SV, Neck?r J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014 Oct; 127(7):463-74. PMID: 24707975.
      View in: PubMed
    81. Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front Pharmacol. 2014; 5:216. PMID: 25295006.
      View in: PubMed
    82. Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol. 2014 Oct 15; 307(8):F971-80. PMID: 25164080.
      View in: PubMed
    83. Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28; 57(16):6965-72. PMID: 25119815.
      View in: PubMed
    84. Hye Khan MA, Neck?r J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther. 2014 Aug; 28(4):313-22. PMID: 24842561.
      View in: PubMed
    85. Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, Pozzi A. Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. J Am Soc Nephrol. 2015 Mar; 26(3):597-610. PMID: 25071086.
      View in: PubMed
    86. Hye Khan MA, Neck?r J, Haines J, Imig JD. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. Am J Hypertens. 2014 Aug; 27(8):1087-95. PMID: 24598210.
      View in: PubMed
    87. Kujal P, Cert?kov? Ch?bov? V, ?karoupkov? P, Huskov? Z, Vernerov? Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Cervenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol. 2014 Mar; 41(3):227-37. PMID: 24471737.
      View in: PubMed
    88. Cabral PD, Hong NJ, Hye Khan MA, Ortiz PA, Beierwaltes WH, Imig JD, Garvin JL. Fructose stimulates Na/H exchange activity and sensitizes the proximal tubule to angiotensin II. Hypertension. 2014 Mar; 63(3):e68-73. PMID: 24379189.
      View in: PubMed
    89. Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem. 2014 Feb 14; 289(7):4377-86. PMID: 24368771.
      View in: PubMed
    90. Mohamed IN, Hafez SS, Fairaq A, Ergul A, Imig JD, El-Remessy AB. Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia. 2014 Feb; 57(2):413-23. PMID: 24201577.
      View in: PubMed
    91. Nagasawa T, Imig JD. Afferent Arteriolar Responses to ?,?-methylene ATP and 20-HETE are not Blocked by ENaC Inhibition. Physiol Rep. 2013 Sep 01; 1(4):e00082. PMID: 24159379.
      View in: PubMed
    92. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97. PMID: 23676336.
      View in: PubMed
    93. Hye Khan MA, Neck?r J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension. 2013 Nov; 62(5):905-13. PMID: 23980070.
      View in: PubMed
    94. Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 2013 Aug; 27(8):2946-56. PMID: 23603837.
      View in: PubMed
    95. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013 Apr; 3(2):957-76. PMID: 23720336.
      View in: PubMed
    96. Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013 Apr; 40(4):273-81. PMID: 23039246.
      View in: PubMed
    97. Honetschl?gerov? Z, Kitada K, Huskov? Z, Sporkov? A, Kopkan L, B?rgelov? M, Varcabov? ?, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Cervenka L. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013 Feb; 31(2):321-32. PMID: 23307303.
      View in: PubMed
    98. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:2-7. PMID: 23333581.
      View in: PubMed
    99. Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, Hammock BD. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor ? agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood). 2012 Dec; 237(12):1402-12. PMID: 23354399.
      View in: PubMed
    100. Kopkan L, Huskov? Z, Sporkov? A, Varcabov? ?, Honetschl?gerov? Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, B?rgelov? M, Vojt?kov? A, Kujal P, Vernerov? Z, Cervenka L. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 2012; 35(6):595-607. PMID: 22948718.
      View in: PubMed
    101. Neck?r J, Kopkan L, Huskov? Z, Kol?r F, Papou?ek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Mal? J, Netuka I, O?t?dal B, Cervenka L. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond). 2012 Jun; 122(11):513-25. PMID: 22324471.
      View in: PubMed
    102. Nagasawa T, Hye Khan MA, Imig JD. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 2012 May; 39(5):454-61. PMID: 22443474.
      View in: PubMed
    103. Bukhari IA, Shah AJ, Gauthier KM, Walsh KA, Koduru SR, Imig JD, Falck JR, Campbell WB. 11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2012 Apr 15; 302(8):H1574-83. PMID: 22307677.
      View in: PubMed
    104. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012 Jan; 92(1):101-30. PMID: 22298653.
      View in: PubMed
    105. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2011 Nov; 301(5):R1307-17. PMID: 21832210.
      View in: PubMed
    106. Zhao X, Zhang Y, Li L, Mann D, Imig JD, Emmett N, Gibbons G, Jin LM. Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. Am J Nephrol. 2011; 34(3):268-80. PMID: 21822010.
      View in: PubMed
    107. Honetschl?gerov? Z, Sporkov? A, Kopkan L, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Ch?bov? VC, Tesar V, Cervenka L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011 Aug; 29(8):1590-601. PMID: 21720266.
      View in: PubMed
    108. Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct; 301(4):F765-72. PMID: 21753077.
      View in: PubMed
    109. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):9038-43. PMID: 21571638.
      View in: PubMed
    110. Khan AH, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens. 2011 Jul; 24(7):816-21. PMID: 21415842.
      View in: PubMed
    111. Sporkov? A, Kopkan L, Varcabov? S, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1468-75. PMID: 21411763.
      View in: PubMed
    112. Imig JD, Simpkins AN, Renic M, Harder DR. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev Mol Med. 2011 Mar 01; 13:e7. PMID: 21356152.
      View in: PubMed
    113. Honetschl?gerov? Z, Huskov? Z, Vanourkov? Z, Sporkov? A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011 Jan 01; 589(Pt 1):207-19. PMID: 21078594.
      View in: PubMed
    114. Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front Physiol. 2010; 1:157. PMID: 21423396.
      View in: PubMed
    115. Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010 Oct; 56(4):329-35. PMID: 20531214.
      View in: PubMed
    116. Imig JD. 20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. Hypertension. 2010 Nov; 56(5):822-3. PMID: 20837886.
      View in: PubMed
    117. Pavlov TS, Imig JD, Staruschenko A. Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. PPAR Res. 2010; 2010:703735. PMID: 20613963.
      View in: PubMed
    118. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010 Oct; 24(10):3770-81. PMID: 20495177.
      View in: PubMed
    119. Walkowska A, Skaroupkov? P, Huskov? Z, Vanourkov? Z, Ch?bov? VC, Tesar V, Kramer HJ, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens. 2010 Mar; 28(3):582-93. PMID: 19940786.
      View in: PubMed
    120. Cert?kov? Ch?bov? V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerov? Z, Vanourkov? Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaneckov? I, Cervenka L. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010 Feb 23; 118(10):617-32. PMID: 20050826.
      View in: PubMed
    121. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci (Lond). 2010 Feb; 118(4):291-301. PMID: 19728860.
      View in: PubMed
    122. Imig JD, Carpenter MA, Shaw S. The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. Pharmaceuticals (Basel). 2009 Dec 18; 2(3):217-227. PMID: 27713235.
      View in: PubMed
    123. Knight SF, Yuan J, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol. 2010 Jan; 298(1):F86-94. PMID: 19906952.
      View in: PubMed
    124. Imig JD. Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. Hypertension. 2009 Dec; 54(6):1223-5. PMID: 19822801.
      View in: PubMed
    125. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct; 8(10):794-805. PMID: 19794443.
      View in: PubMed
    126. Quigley R, Chakravarty S, Zhao X, Imig JD, Capdevila JH. Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. Nephron Physiol. 2009; 113(4):p23-8. PMID: 19713718.
      View in: PubMed
    127. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009 Sep; 297(3):F740-8. PMID: 19553349.
      View in: PubMed
    128. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009 Jun; 174(6):2086-95. PMID: 19435785.
      View in: PubMed
    129. Sudhahar V, Shaw S, Imig JD. Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. Eur J Pharmacol. 2009 Apr 01; 607(1-3):143-50. PMID: 19326479.
      View in: PubMed
    130. Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, Imig JD. Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2009 Jul; 36(7):724-8. PMID: 19207724.
      View in: PubMed
    131. Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009 Jan; 116(1):61-70. PMID: 18459944.
      View in: PubMed
    132. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia. 2008 Oct; 10(10):1092-104. PMID: 18813349.
      View in: PubMed
    133. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 2008 Dec; 22(12):4096-108. PMID: 18716027.
      View in: PubMed
    134. Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, Harris RC. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem. 2008 Sep 05; 283(36):24514-24. PMID: 18606824.
      View in: PubMed
    135. Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb; 4(2):165-74. PMID: 18248310.
      View in: PubMed
    136. Imig JD, Dimitropoulou C, Reddy DS, White RE, Falck JR. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. Microcirculation. 2008 Feb; 15(2):137-50. PMID: 18260004.
      View in: PubMed
    137. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension. 2008 Feb; 51(2):352-9. PMID: 18158349.
      View in: PubMed
    138. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008 Jan; 294(1):R76-83. PMID: 17989143.
      View in: PubMed
    139. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension. 2007 Dec; 50(6):1069-76. PMID: 17938380.
      View in: PubMed
    140. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res. 2007 Oct; 5(10):1015-30. PMID: 17951402.
      View in: PubMed
    141. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007 Sep; 117(9):2496-505. PMID: 17710229.
      View in: PubMed
    142. Cert?kov? Ch?bov? V, Kramer HJ, Vaneckov? I, Thumov? M, Skaroupkov? P, Tesar V, Falck JR, Imig JD, Cervenka L. The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 2007; 30(5):335-46. PMID: 17785988.
      View in: PubMed
    143. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol. 2007 Oct; 171(4):1104-12. PMID: 17717147.
      View in: PubMed
    144. Ch?bov? VC, Kramer HJ, Vaneckov? I, Vernerov? Z, Eis V, Tesar V, Skaroupkov? P, Thumov? M, Schejbalov? S, Huskov? Z, Vanourkov? Z, Kolsk? A, Imig JD, Cervenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007 Aug-Sep; 47(2-3):145-59. PMID: 17604232.
      View in: PubMed
    145. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation. 2007 Jun-Jul; 14(4-5):349-62. PMID: 17613807.
      View in: PubMed
    146. Kang KT, Sullivan JC, Sasser JM, Imig JD, Pollock JS. Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. Hypertension. 2007 Apr; 49(4):893-901. PMID: 17309950.
      View in: PubMed
    147. Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD. Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):50-61. PMID: 17259072.
      View in: PubMed
    148. Elmarakby AA, Williams JM, Imig JD, Pollock JS, Pollock DM. Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. Vascul Pharmacol. 2007 Feb; 46(2):144-51. PMID: 17112788.
      View in: PubMed
    149. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (Lond). 2006 Jul; 111(1):21-34. PMID: 16764555.
      View in: PubMed
    150. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006 Sep; 318(3):1307-14. PMID: 16772540.
      View in: PubMed
    151. Jin L, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, Webb RC. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther. 2006 Jul; 318(1):288-95. PMID: 16569756.
      View in: PubMed
    152. Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006 Jun; 290(6):H2187-95. PMID: 16501022.
      View in: PubMed
    153. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006 Mar; 47(3):557-62. PMID: 16415373.
      View in: PubMed
    154. Jin L, Foss CE, Zhao X, Mills TM, Wang MH, McCluskey LP, Yaddanapud GS, Falck JR, Imig JD, Webb RC. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J. 2006 Mar; 20(3):539-41. PMID: 16415108.
      View in: PubMed
    155. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev. 2006; 24(2):169-88. PMID: 16961727.
      View in: PubMed
    156. Inscho EW, Imig JD, Cook AK, Pollock DM. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol. 2005 Dec; 146(7):1019-26. PMID: 16231007.
      View in: PubMed
    157. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005 Dec; 46(6):842-8. PMID: 16306811.
      View in: PubMed
    158. Lee DL, Sturgis LC, Labazi H, Osborne JB, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006 Mar; 290(3):H935-40. PMID: 16284237.
      View in: PubMed
    159. Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R435-41. PMID: 16239374.
      View in: PubMed
    160. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 Oct; 46(4):975-81. PMID: 16157792.
      View in: PubMed
    161. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F496-503. PMID: 16093425.
      View in: PubMed
    162. Zhao X, Cook AK, Field M, Edwards B, Zhang S, Zhang Z, Pollock JS, Imig JD, Inscho EW. Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. Hypertension. 2005 Sep; 46(3):562-8. PMID: 16116048.
      View in: PubMed
    163. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005 Aug; 46(2):366-71. PMID: 15967866.
      View in: PubMed
    164. Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, Awayda MS, Imig JD, Inscho EW, Navar LG. Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol. 2005 Oct; 289(4):F760-7. PMID: 15942047.
      View in: PubMed
    165. Imig JD, Zhao X, Dey A, Shaw M. CYP450, COX-2 and Obesity Related Renal Damage. Toxicol Mech Methods. 2005; 15(2):125-36. PMID: 20021073.
      View in: PubMed
    166. Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond). 2004 Dec; 107(6):561-70. PMID: 15307815.
      View in: PubMed
    167. Pollock DM, Jenkins JM, Cook AK, Imig JD, Inscho EW. L-type calcium channels in the renal microcirculatory response to endothelin. Am J Physiol Renal Physiol. 2005 Apr; 288(4):F771-7. PMID: 15547114.
      View in: PubMed
    168. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2005 Jan; 288(1):R188-96. PMID: 15345471.
      View in: PubMed
    169. Zhao X, Falck JR, Gopal VR, Inscho EW, Imig JD. P2X receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. J Pharmacol Exp Ther. 2004 Dec; 311(3):1211-7. PMID: 15316085.
      View in: PubMed
    170. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res. 2004 Aug; 12(8):1278-89. PMID: 15340111.
      View in: PubMed
    171. Imig JD. 20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? Am J Physiol Regul Integr Comp Physiol. 2004 Jul; 287(1):R3-5. PMID: 15191921.
      View in: PubMed
    172. Sullivan JC, Loomis ED, Collins M, Imig JD, Inscho EW, Pollock JS. Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. J Appl Physiol (1985). 2004 Oct; 97(4):1268-74. PMID: 15169747.
      View in: PubMed
    173. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004 May; 15(5):1244-53. PMID: 15100364.
      View in: PubMed
    174. Inscho EW, Cook AK, Murzynowski JB, Imig JD. Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. J Hypertens. 2004 Apr; 22(4):811-8. PMID: 15126924.
      View in: PubMed
    175. Imig JD. ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. Hypertension. 2004 Mar; 43(3):533-5. PMID: 14757781.
      View in: PubMed
    176. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest. 2003 Dec; 112(12):1895-905. PMID: 14679185.
      View in: PubMed
    177. Yiu SS, Zhao X, Inscho EW, Imig JD. 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. J Lipid Res. 2003 Dec; 44(12):2391-9. PMID: 12951362.
      View in: PubMed
    178. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension. 2003 Oct; 42(4):594-9. PMID: 12939236.
      View in: PubMed
    179. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003 Oct; 42(4):775-80. PMID: 12900436.
      View in: PubMed
    180. Imig JD, Zhao X, Orengo SR, Dipp S, El-Dahr SS. The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides. 2003 Aug; 24(8):1141-7. PMID: 14612184.
      View in: PubMed
    181. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003 Mar; 41(3 Pt 2):709-14. PMID: 12623984.
      View in: PubMed
    182. Imig JD, Breyer MD, Breyer RM. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol. 2002 Sep; 283(3):F415-22. PMID: 12167591.
      View in: PubMed
    183. Harrison-Bernard LM, Imig JD, Carmines PK. Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res. 2002 Apr-Jun; 3(2):97-108. PMID: 11991202.
      View in: PubMed
    184. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002 Feb; 39(2 Pt 2):690-4. PMID: 11882632.
      View in: PubMed
    185. Imig JD, Inscho EW. Adaptations of the renal microcirculation to hypertension. Microcirculation. 2002; 9(4):315-28. PMID: 12152107.
      View in: PubMed
    186. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG. Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension. 2002 Jan; 39(1):116-21. PMID: 11799089.
      View in: PubMed
    187. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the Mystery of Goldblatt Hypertension. News Physiol Sci. 1998 Aug; 13:170-176. PMID: 11390784.
      View in: PubMed
    Imig's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (555) concept(s)
    _
    Similar People Expand Description
    See all (30) people
    _
    Same Department Expand Description
    Search Department